β 2 -adrenergic agonists having the potential to be misused to enhance performance for their thermogenic and anabolic properties are prohibited in sports. Clenbuterol, ractopamine and zilpaterol are utilised legally or illegally as growth promoters of animals raised for their meat. No withdrawal times are imposed for ractopamine prior to slaughter; residues are detected in meat of treated animals, which constitutes a risk of inadvertent consumption. Insufficient information is available on the fate of ractopamine in humans to implement efficient detection in athletes' urine samples. We have developed a confirmation procedure for total ractopamine in urine following the enzymatic hydrolysis of glucuronides and sulphates and the conversion to tri-TMS derivative (limit of identification at 0.15 ng/ml). The sulphates were found to form between 85% to 97% of ractopamine excreted in athletes' urine samples analysed routinely or in volunteers following the administration of a micro-dose of 2.5 μg. Peak levels were reached at 2 to 6 h and decreased rapidly below 1 ng/ml 10 h after dosing. With one exception, the highest level estimated in athletes' samples was 1.2 ng/ml. Zilpaterol was confirmed in a few urine samples collected in the USA and Mexico (highest level 2 ng/ml), while hundreds of athletes' samples were reported to contain clenbuterol by our laboratory over the past 7 years. Most of these cases originated from Mexico (n = 102) and Guatemala (n = 119), often clustered in events during which multiple samples were collected, and for the vast majority, in levels lower than 0.2 ng/ml. K E Y W O R D S clenbuterol, GC-MS/MS, ractopamine, zilpaterol, β2-agonists 1 | INTRODUCTION β 2 -adrenergic agonists are banned in sports, listed in section S3 of the World Anti-Doping Code Prohibited List of Substances and Methods. However, clenbuterol, ractopamine, and zilpaterol are specifically considered to be anabolic agents, under section S1.2 other anabolic agents and therefore, are always banned. 1 The abuse of clenbuterol ((RS)-1-(4-amino-3,5-dichlorophenyl)-2-(tert-butylamino) ethanol, CLEN) in athletes was documented in the 1990s 2 with the first positive case reported in June 1992 marking its inclusion on the IOC prohibited list. Its thermogenic and anabolic effects were suggested by Rothwell and Stock 3 following administration studies in lean and genetically obese rodents. More recently Jessen et al. 4 concluded that CLEN was an 'efficient thermogenic substance' that 'may exert anabolic actions in human skeletal muscle'. CLEN findings are frequently reported; with the implementation of high-sensitivity GC-MS/MS detection methods, the number of cases reported by WADA accredited laboratories went from approximately